Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 80
Filtrar
3.
Geburtshilfe Frauenheilkd ; 37(2): 131-8, 1977 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-838261

RESUMEN

Following the introduction of massive triple drug therapy with high doses of Endoxan, Proresid and Methotrexat instead of the earlier long-term Endoxan treatment in addition of surgery, percutaneous irradiation and intraperitoneal radio-gold, 3 year survival of advanced stages IIb-IV of ovarian carcinoma rose from 19.6% to 42.6%. The 3 year survival of all malignant ovarian tumors (primary or secondary) rose from 38.3% to 51.0%. Further development led to targeted multiple drug therapy (ultrahigh Endoxan, Proresid/VM26, Methotrexat and Adriblastin) according to oncobiogram. The main side-effects, their control and experience with combined chemotherapy and irradiation are described.


Asunto(s)
Neoplasias Ováricas/tratamiento farmacológico , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Quimioterapia Combinada , Femenino , Radioisótopos de Oro , Humanos , Metotrexato/uso terapéutico , Neoplasias Ováricas/radioterapia , Fitoterapia , Plantas Medicinales , Plantas Tóxicas , Podophyllum/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA